What does DPYD stand for?

Dihydropyrimidine Dehydrogenase

This definition appears very rarely and is found in the following Acronym Finder categories:

Science, medicine, engineering, etc.

Other Resources:

<< Previous	Abbreviation Database Surfer		Next >>
Dextropropoxyphène Di-N-Butyle Phthalate in Xylene Diffuse Plane Xanthoma Digital Phosphor Technology (Tektronix) Digital Picture Exchange Dusty Plasma Experiment Department of Physics Democrat Party Youth Action (Thailand) Dana Point Youth Baseball (California) Dana Point Yacht Club (Dana Point, CA)		National Democratic Party Youth Forum (political party; Albania) Drug Proof Your Kids Don't Push Your Luck Dayton Philharmonic Youth Orchestra (Ohio) Dihydropyrimidinase Dihydropyrimidinase-Like Defense Plant Zone Department of Planning and Zoning Deutsche Primaten Zentrum (German, Gottingen) Dienst Personele Zaken (Dutch: Service Personnel Department)

Samples in periodicals archive:

It has been suggested that CRC tumours respond to 5-FU when there are low TS, dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP) expression levels [6].

A randomized Phase II trial of pemetrexed plus irinotecan (ALIRI) ...

Abstract: Dihydropyrimidine dehydrogenase (DPD) is one of the factors that determine the efficacy and toxicity of 5-fluorouracil.

Suppression of DPYD expression in RKO cells via DNA methylation in ...

Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications.

ADHEREX GETS NEW DRUG IND CLEARANCE FOR ENILURACIL

Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications.

Adherex reports 2005 Fiscal Results

Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications.

Adherex Receives Regulatory Clearance For Phase II Weekly Dosing ...

Eniluracil, an oral dihydropyrimidine dehydrogenase (DPD) inhibitor, was previously under development by GlaxoSmithKline for oncology indications.

Adherex CEO a Panelist at BIO CEO & Investor Conference 2006

Therefore, eniluracil not only irreversibly inhibits the enzyme dihydropyrimidine dehydrogenase (DPD) which breaks down 5-fluorouracil (5-FU), it can also reversibly inhibit the activation of 5-FU, thereby limiting the effectiveness of 5-FU as an anti-cancer agent when not dosed properly.

5-FU Expert Presents Data Supporting Adherex's Approach to ...

Eniluracil Adherex in-licensed eniluracil, an irreversible inhibitor of dihydropyrimidine dehydrogenase (DPD), from GlaxoSmithKline in July 2005.

Adherex Announces Corporate Goals for 2006